ELC-401
Elicera CEO: "TO2 a very attractive opportunity to increase ownership in Elicera"
Cell and gene therapy company Elicera Therapeutics entered the market stronger
Elicera CEO: “One of the biggest milestones in our history”
Elicera Therapeutics has officially entered clinical...
Emission to take Elicera's ELC-301 through clinical trial
Cell and gene therapy specialist Elicera Therapeutics is on its way...
Full speed ahead for Elicera in 2024
Elicera Therapeutics has started operations in 2024. The Swedish cell...
Elicera CEO: "iTANK has high potential in the treatment of solid tumors"
Elicera's Q3 report was a read packed with updates...
Elicera Therapeutics secures important EU patent
The European Patent Office intends to approve Elicera's patent application...
Elicera updates in conjunction with Cancer Immunotherapy Month
June is celebrated globally as Cancer Immunotherapy Month in...
Well-funded Elicera prepared for clinic and business development
Cell and gene therapy company Elicera Therapeutics has made important...
Advancement in Eliceras 2022 opens up for intensive clinical year
In 2022, Elicera Therapeutics advanced – the only...
Elicera on AstraZeneca's acquisition of Neogene Therapeutics
Interest in cell treatments is on the rise, which is noticeable...
Elicera about the positive clinical effect in the cancer study
Elicera Therapeutics recently participated in the Oncolytic Virotherapy Summit...
Elicera CEO: "iTANK partnering is intensifying"
Elicera Therapeutics is in an advantageous position,...